tyrosine 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |

Stem definitionDrug idCAS RN
2786 60-18-4

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • tyrosine
  • L-Tyrosine
  • (S)-Tyrosine
A non-essential amino acid. In animals it is synthesized from PHENYLALANINE. It is also the precursor of EPINEPHRINE; THYROID HORMONES; and melanin.
  • Molecular weight: 181.19
  • Formula: C9H11NO3
  • CLOGP: -2.22
  • LIPINSKI: 0
  • HAC: 4
  • HDO: 3
  • TPSA: 83.55
  • ALOGS: -1.37
  • ROTB: 3
  • Status: OFM
    • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

None

ADMET properties:

None

Predicted pharmacokinetic/toxicological properties (PK-AZ):

PropertyDescriptionValueUnitConfidenceSimilarity
azlogd74 LogD at pH 7.4 -2.608 Moderate 0.67
caco2-efflux Caco-2 efflux ratio (BA/AB) 0.214 Moderate 0.67
caco2-intrinsic-papp Caco-2 intrinsic apparent permeability 0.820 10^-6 cm/s Moderate 0.67
dh-clint Dog hepatocyte intrinsic clearance 0.959 uL/min/10^6 cells Moderate 0.67
dppb Dog plasma protein binding (% unbound) 89.460 % Moderate 0.67
fcs-ppb Fetal calf serum protein binding (% unbound) 80.870 % Moderate 0.67
herg hERG pIC50 5.021 pIC50 Moderate 0.67
hh-clint Human hepatocyte intrinsic clearance 2.178 uL/min/10^6 cells Moderate 0.67
hlm-clint Human liver microsomal intrinsic clearance 3.597 uL/min/mg protein Moderate 0.67
hppb Human plasma protein binding (% unbound) 93.350 % Moderate 0.67
kinase-safety-class ACVR2A,ACVR2B,AURKA,AXL,BRAF,BTK,CAMK2D,CDK4,CDK5,CDK9,DDR1,DYRK1B,EGFR,EIF2AK3,EPHB4,ERBB2,GRK2,ITK,JAK2,JAK3,MAP2K6,MAP3K21,MAP3K7,MAPK10,MAPK7,MAPKAPK2,NTRK2,PDK1,PDK2,PIK3CB,PIM2,PRKDC,SIK2,STK33,SYK,TEK,TGFBR1,ZAP70 38
kinase-selectivity-class AXL,GRK2,MAP2K6 3
mdck-mdr1-bcrp-efflux MDCK-MDR1-BCRP efflux ratio 0.304 Moderate 0.65
mdck-mdr1-efflux MDCK-MDR1 efflux ratio 0.853 Moderate 0.67
mh-clint Mouse hepatocyte intrinsic clearance 1.820 Moderate 0.67
mppb Mouse plasma protein binding (% unbound) 96.630 Moderate 0.67
nih-mdck-mdr1-efflux NIH MDCK-MDR1 efflux ratio 0.346 Moderate 0.67
pfas-class PFAS structural alert (1 = True, 0 = False) 0
pppb Pig plasma protein binding (% unbound) 91.750 % Moderate 0.67
rat-kpuu-brain Rat brain Kpuu 0.018 % Moderate 0.65
rh-clint Rat hepatocyte intrinsic clearance 1.199 uL/min/10^6 cells Moderate 0.67
rh-fuinc Rat hepatocyte fraction unbound in incubation 88.630 % Moderate 0.67
rppb Rat plasma protein binding (% unbound) 88.470 % Moderate 0.67
solubility-dd Solubility at pH 7.4 in DMSO 826.038 uM Moderate 0.67

Approvals:

DateAgencyCompanyOrphan
None FDA

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Foetal growth restriction 62.55 22.23 15 821 9365 90618246
Infantile apnoea 44.15 22.23 8 828 1279 90626332
Selective eating disorder 40.43 22.23 8 828 2045 90625566
Cerebral haemorrhage 31.95 22.23 12 824 34510 90593101
Device related sepsis 28.53 22.23 7 829 4786 90622825

FDA Adverse Event Reporting System (Male)

None

FDA Adverse Event Reporting System (Geriatric)

None

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
CHEBI has role CHEBI:27027 micronutrient
CHEBI has role CHEBI:50733 nutraceutical
CHEBI has role CHEBI:64416 EC 1.3.1.43 (arogenate dehydrogenase) inhibitor
CHEBI has role CHEBI:78675 fundamental metabolite
CHEBI has role CHEBI:83056 <em>Daphnia magna</em> metabolite

Drug Use | Suggest Off label Use Form| |View source of the data|

None




🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 2.27 acidic
pKa2 10.4 acidic
pKa3 9.25 Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])		Mechanism
action		Bioact sourceMoA source
Large neutral amino acids transporter small subunit 1 Transporter IC50 4.17 CHEMBL

External reference:

IDSource
4018678 VUID
N0000146989 NUI
D00022 KEGG_DRUG
4018678 VANDF
C0041485 UMLSCUI
CHEBI:17895 CHEBI
TYR PDB_CHEM_ID
CHEMBL925 ChEMBL_ID
DB00135 DRUGBANK_ID
D014443 MESH_DESCRIPTOR_UI
6057 PUBCHEM_CID
6174 INN_ID
42HK56048U UNII
10962 RXNORM
15487 MMSL
187423 MMSL
40047 MMSL
NOCODE MMSL
d07831 MMSL
003449 NDDF
27378009 SNOMEDCT_US
418246001 SNOMEDCT_US
4791 IUPHAR_LIGAND_ID

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
TrophAmine HUMAN PRESCRIPTION DRUG LABEL 20 0264-1933 SOLUTION 0.04 g INTRAVENOUS NDA 23 sections
Plenamine HUMAN PRESCRIPTION DRUG LABEL 17 0264-4500 SOLUTION 39 mg INTRAVENOUS ANDA 20 sections
CLINIMIX HUMAN PRESCRIPTION DRUG LABEL 16 0338-0180 INJECTION 32 mg INTRAVENOUS NDA 21 sections
CLINIMIX HUMAN PRESCRIPTION DRUG LABEL 16 0338-0184 INJECTION 32 mg INTRAVENOUS NDA 21 sections
CLINIMIX HUMAN PRESCRIPTION DRUG LABEL 16 0338-0188 INJECTION 32 mg INTRAVENOUS NDA 21 sections
CLINIMIX HUMAN PRESCRIPTION DRUG LABEL 16 0338-0194 INJECTION 32 mg INTRAVENOUS NDA 21 sections
CLINIMIX HUMAN PRESCRIPTION DRUG LABEL 16 0338-0198 INJECTION 24 mg INTRAVENOUS NDA 21 sections
CLINIMIX E HUMAN PRESCRIPTION DRUG LABEL 20 0338-0202 INJECTION 32 mg INTRAVENOUS NDA 20 sections
CLINIMIX E HUMAN PRESCRIPTION DRUG LABEL 20 0338-0206 INJECTION 32 mg INTRAVENOUS NDA 20 sections
CLINIMIX E HUMAN PRESCRIPTION DRUG LABEL 20 0338-0210 INJECTION 32 mg INTRAVENOUS NDA 20 sections
CLINIMIX E HUMAN PRESCRIPTION DRUG LABEL 20 0338-0214 INJECTION 32 mg INTRAVENOUS NDA 20 sections
ProSol HUMAN PRESCRIPTION DRUG LABEL 17 0338-0499 INJECTION, SOLUTION 50 mg INTRAVENOUS NDA 21 sections
Clinisol HUMAN PRESCRIPTION DRUG LABEL 17 0338-0502 INJECTION, SOLUTION 39 mg INTRAVENOUS ANDA 18 sections
Travasol HUMAN PRESCRIPTION DRUG LABEL 15 0338-0644 INJECTION 40 mg INTRAVENOUS NDA 20 sections
CLINIMIX HUMAN PRESCRIPTION DRUG LABEL 16 0338-1089 INJECTION 17 mg INTRAVENOUS NDA 21 sections
CLINIMIX HUMAN PRESCRIPTION DRUG LABEL 16 0338-1091 INJECTION 17 mg INTRAVENOUS NDA 21 sections
CLINIMIX HUMAN PRESCRIPTION DRUG LABEL 16 0338-1099 INJECTION 20 mg INTRAVENOUS NDA 21 sections
CLINIMIX HUMAN PRESCRIPTION DRUG LABEL 16 0338-1101 INJECTION 20 mg INTRAVENOUS NDA 21 sections
CLINIMIX E HUMAN PRESCRIPTION DRUG LABEL 21 0338-1113 INJECTION 17 mg INTRAVENOUS NDA 20 sections
CLINIMIX E HUMAN PRESCRIPTION DRUG LABEL 21 0338-1115 INJECTION 17 mg INTRAVENOUS NDA 20 sections
CLINIMIX E HUMAN PRESCRIPTION DRUG LABEL 21 0338-1123 INJECTION 20 mg INTRAVENOUS NDA 20 sections
CLINIMIX E HUMAN PRESCRIPTION DRUG LABEL 21 0338-1125 INJECTION 20 mg INTRAVENOUS NDA 20 sections
Premasol - sulfite-free (Amino Acid) HUMAN PRESCRIPTION DRUG LABEL 19 0338-1130 INJECTION, SOLUTION 0.24 g INTRAVENOUS ANDA 15 sections
Premasol - sulfite-free (Amino Acid) HUMAN PRESCRIPTION DRUG LABEL 19 0338-1131 INJECTION, SOLUTION 0.14 g INTRAVENOUS ANDA 15 sections
CLINIMIX HUMAN PRESCRIPTION DRUG LABEL 16 0338-1133 INJECTION 17 mg INTRAVENOUS NDA 21 sections
CLINIMIX HUMAN PRESCRIPTION DRUG LABEL 16 0338-1134 INJECTION 17 mg INTRAVENOUS NDA 21 sections
CLINIMIX HUMAN PRESCRIPTION DRUG LABEL 16 0338-1137 INJECTION 20 mg INTRAVENOUS NDA 21 sections
CLINIMIX HUMAN PRESCRIPTION DRUG LABEL 16 0338-1138 INJECTION 20 mg INTRAVENOUS NDA 21 sections
CLINIMIX E HUMAN PRESCRIPTION DRUG LABEL 21 0338-1142 INJECTION 11 mg INTRAVENOUS NDA 20 sections
CLINIMIX E HUMAN PRESCRIPTION DRUG LABEL 21 0338-1144 INJECTION 17 mg INTRAVENOUS NDA 20 sections